The US FDA has approved a combination of nivolumab and hyaluronidase as a subcutaneous injection for treating adults with solid tumors, including renal cell carcinoma, melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, urothelial carcinoma, hepatocellular carcinoma, and colorectal, esophageal, and gastric cancers. It is indicated as monotherapy, monotherapy maintenance following completion of nivolumab and ipilimumab combination therapy, or in combination with chemotherapy or cabozantinib. Clinical evidence In a clinical trial involving 495 adult patients with advanced or metastatic clear cell renal cell carcinoma, the combination therapy demonstrated non-inferior co-primary pharmacokinetic exposures and comparable efficacy in achieving the overall response rate compared to intravenous nivolumab treatment (24% vs.
18%). Dosage and administration Subcutaneous…
